Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425634 | 0.81 | KMT2A (0.54) | KMT2AMEN1OPRK1TDP1LMNA | |
| SCHEMBL6067593 | 0.78 | KMT2A (0.57) | KMT2AMEN1OPRK1TDP1LMNA | |
| SCHEMBL1818825 | 0.75 | LTA4H (0.55) | KMT2AMEN1OPRK1TDP1LMNA | |
| SCHEMBL27476119 | 0.75 | OPRK1 (0.66) | KMT2AMEN1OPRK1TDP1LMNA | |
| SCHEMBL1930736 | 0.75 | KMT2A (0.70) | KMT2AMEN1OPRK1TDP1LMNA | |
| SCHEMBL12291744 | 0.74 | KMT2A (0.75) | KMT2AMEN1OPRK1TDP1LMNA | |
| SCHEMBL20769767 | 0.74 | KMT2A (0.64) | KMT2AMEN1OPRK1TDP1LMNA | |
| SCHEMBL10329430 | 0.73 | OPRK1 (0.62) | KMT2AMEN1OPRK1TDP1LMNA | |
| SCHEMBL4121702 | 0.73 | OPRK1 (0.62) | KMT2AMEN1OPRK1TDP1LMNA | |
| SCHEMBL4121655 | 0.72 | KMT2A (0.57) | KMT2AMEN1OPRK1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722864-B2 | Glycosylated acetaminophen pro-drug analogs | NuTek Pharma Ltd. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130217640-A1 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG | NuTek Pharma Ltd. | 2013-08-22 | — | — | US | disclosed |
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | UGT1A3, GCG, UGT1A1 | KMT2A 4128/4885MEN1 4056/4885OPRK1 38/4885 |
| US-20130217640-A1 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG | UGT1A3, GCG, UGGT1 | KMT2A 4023/4885MEN1 4207/4885OPRK1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.